Karamitopoulou, Eva

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 22.

Journal Article

Karamitopoulou, Eva; Wenning, Anna Silvia; Acharjee, Animesh; Aeschbacher, Pauline; Marinoni, Ilaria; Zlobec, Inti; Gloor, Beat; Perren, Aurel (2024). Spatial heterogeneity of immune regulators drives dynamic changes of local immune responses, affecting disease outcomes in pancreatic cancer. Clinical cancer research, 30(18), pp. 4215-4226. American Association for Cancer Research 10.1158/1078-0432.CCR-24-0368

Karamitopoulou, Eva (2023). Emerging prognostic and predictive factors in pancreatic cancer. Modern pathology, 36(11), p. 100328. Elsevier 10.1016/j.modpat.2023.100328

Karamitopoulou, Eva; Wenning, Anna Silvia; Acharjee, Animesh; Zlobec, Inti; Aeschbacher, Pauline; Perren, Aurel; Gloor, Beat (2023). Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut, 72(8), pp. 1523-1533. BMJ Publishing Group 10.1136/gutjnl-2022-329371

Ferguson, L Paige; Gatchalian, Jovylyn; McDermott, Matthew L; Nakamura, Mari; Chambers, Kendall; Rajbhandari, Nirakar; Lytle, Nikki K; Rosenthal, Sara Brin; Hamilton, Michael; Albini, Sonia; Wartenberg, Martin; Zlobec, Inti; Galván Hernández, José Alberto; Karamitopoulou, Eva; Vavinskaya, Vera; Wascher, Alexis; Lowy, Andrew M; Schürch, Christian M; Puri, Pier Lorenzo; Bruneau, Benoit G; ... (2023). Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Nature Communications, 14(1), p. 292. Springer Nature 10.1038/s41467-023-35796-7

Zeng, Qiqun; Saghafinia, Sadegh; Chryplewicz, Agnieszka; Fournier, Nadine; Christe, Lucine; Xie, Yu-Qing; Guillot, Jeremy; Yucel, Simge; Li, Pumin; Galván, José A; Karamitopoulou, Eva; Zlobec, Inti; Ataca, Dalya; Gallean, Fleuriane; Zhang, Peng; Rodríguez-Calero, José Antonio; Rubin, Mark; Tichet, Mélanie; Homicsko, Krisztian and Hanahan, Douglas (2022). Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion. Science, 378(6621), eabl7207. American Association for the Advancement of Science 10.1126/science.abl7207

Karamitopoulou, Eva; Andreou, Andreas; Wenning, Anna Silvia; Gloor, Beat; Perren, Aurel (2022). High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. European journal of cancer, 169, pp. 64-73. Elsevier 10.1016/j.ejca.2022.03.033

Karamitopoulou, Eva (2022). Molecular Pathology of Pancreatic Cancer. Cancers, 14(6) MDPI AG 10.3390/cancers14061523

Carrasco-Garcia, Estefania; Lopez, Lidia; Moncho-Amor, Veronica; Carazo, Fernando; Aldaz, Paula; Collado, Manuel; Bell, Donald; Gaafar, Ayman; Karamitopoulou, Eva; Tzankov, Alexandar; Hidalgo, Manuel; Rubio, Ángel; Serrano, Manuel; Lawrie, Charles H; Lovell-Badge, Robin; Matheu, Ander (2022). SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers, 14(4) MDPI AG 10.3390/cancers14040916

Karamitopoulou, Eva; Andreou, Andreas; Pahud de Mortanges, Aurélie; Tinguely, Marianne; Gloor, Beat; Perren, Aurel (2021). PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups. Cancer immunology research, 9(12), pp. 1439-1450. American Association for Cancer Research 10.1158/2326-6066.CIR-21-0144

Sadozai, Hassan; Acharjee, Animesh; Gruber, Thomas; Gloor, Beat; Karamitopoulou, Eva (2021). Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity. Cancers, 13(5) MDPI AG 10.3390/cancers13051090

Karamitopoulou, Eva; Gloor, B. (2013). Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment. European journal of cancer, 49(10), pp. 2458-2459. Elsevier 10.1016/j.ejca.2013.03.028

Karamitopoulou, Eva (2012). Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Frontiers in oncology, 2, p. 209. Lausanne: Frontiers Research Foundation 10.3389/fonc.2012.00209

Horcic, Milo; Koelzer, Viktor H; Karamitopoulou, Eva; Terracciano, Luigi; Puppa, Giacomo; Zlobec, Inti; Lugli, Alessandro (2012). Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Human pathology, 44(5), pp. 697-705. Philadelphia, Pa.: Elsevier 10.1016/j.humpath.2012.07.026

Lugli, A; Karamitopoulou, Eva; Zlobec, I (2012). Tumour budding: a promising parameter in colorectal cancer. British journal of cancer, 106(11), pp. 1713-7. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.127

Piscuoglio, Salvatore; Zlobec, Inti; Pallante, Pierlorenzo; Sepe, Romina; Esposito, Francesco; Zimmermann, Arthur; Diamantis, Ioannis; Terracciano, Luigi; Fusco, Alfredo; Karamitopoulou, Eva (2012). HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology, 60(3), pp. 397-404. Oxford: Blackwell Scientific Publications 10.1111/j.1365-2559.2011.04121.x

Tsapralis, Dimitrios; Panayiotides, Ioannis; Peros, George; Liakakos, Theodore; Karamitopoulou, Eva (2012). Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World journal of gastroenterology, 18(2), pp. 150-5. Beijing (China): WJG Press 10.3748/wjg.v18.i2.150

Lugli, Alessandro; Vlajnic, Tatjana; Giger, Olivier; Karamitopoulou, Eva; Patsouris, Efstratios S; Peros, George; Terracciano, Luigi M; Zlobec, Inti (2011). Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Human pathology, 42(12), pp. 1833-40. Philadelphia, Pa.: Elsevier 10.1016/j.humpath.2011.02.010

Karamitopoulou, Eva; Zlobec, Inti; Tornillo, Luigi; Carafa, Vincenza; Schaffner, Thomas; Brunner, Thomas; Borner, Markus; Diamantis, Ioannis; Zimmermann, Arthur; Terracciano, Luigi (2010). Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology, 42(3), pp. 229-34. London: Wolters Kluwer Lippincott Williams & Wilkins 10.3109/00313021003631379

Karamitopoulou, Eva; Pallante, Pierlorenzo; Zlobec, Inti; Tornillo, Luigi; Carafa, Vincenza; Schaffner, Thomas; Borner, Markus; Diamantis, Ioannis; Esposito, Francesco; Brunner, Thomas; Zimmermann, Arthur; Federico, Antonella; Terracciano, Luigi; Fusco, Alfredo (2010). Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. European journal of cancer, 46(8), pp. 1438-44. Amsterdam: Elsevier 10.1016/j.ejca.2010.01.033

Karamitopoulou, Eva; Rentsch, Cyrill A; Markwalder, Regula; Vallan, Claudio; Thalmann, George N; Brunner, Thomas (2010). Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology, 42(1), pp. 37-42. London: Wolters Kluwer Lippincott Williams & Wilkins 10.3109/00313020903434397

Karamitopoulou, Eva; Tornillo, Luigi; Zlobec, Inti; Cioccari, Lukas; Carafa, Vincenza; Borner, Markus; Schaffner, Thomas; Brunner, Thomas; Diamantis, Ioannis; Zimmermann, Arthur; Terracciano, Luigi (2008). Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. American journal of clinical pathology, 130(5), pp. 780-6. Chicago, Ill.: American Society for Clinical Pathology 10.1309/AJCP35FDCAVANWMM

Karamitopoulou, Eva; Cioccari, Luca; Jakob, Sabine; Vallan, Claudio; Schaffner, Thomas; Zimmermann, Arthur; Brunner, Thomas (2007). Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours. Pathology, 39(6), pp. 558-64. London: Wolters Kluwer Lippincott Williams & Wilkins 10.1080/00313020701684375

This list was generated on Sat Dec 21 15:38:05 2024 CET.
Provide Feedback